Trademark Overview
On Tuesday, December 10, 2024, a trademark application was filed for GRAFALON with the United States Patent and Trademark Office. The USPTO has given the GRAFALON trademark a serial number of 79414175. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Friday, December 19, 2025. This trademark is owned by Neovii Biotech GmbH. The GRAFALON trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical services; medical, pharmaceutical and biopharmaceutical services in the nature of medical and pharmaceutical consultation and medical advice and information in the field of oncology, hematology, stem cell transplantation, organ transplantation and immunological therapy.
Scientific services and research for medical purposes, namely medical and scientific research in the field of cell biology and antibodies and immunology; scientific and technological services, namely scientific research, analysis, testing in the field of biotechnology, biopharmaceutics and medical science; biotechnological and biopharmaceutical analyses, namely blood analysis services for scientific research purpose, cell analysis services for scientific research purpose, DNA analysis services for scientific research purpose, human leukocyte antigen (HLA) analysis services for scientific research purpose , antibodies analysis services for scientific research purpose, antigen analysis services for scientific research purposes, Technical research in the field of pharmaceutical studies; medical research laboratory services.
Pharmaceutical compositions and preparations, namely, pharmaceutical preparations for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis, aplastic anemia, autoimmune diseases, diabetes, and for the prevention and treatment of graft-versus-host disease, hemophagocytic lymphohistiocytosis, lupus nephritis, multiple sclerosis, myelodysplastic syndrome, myelofibrosis, systemic lupus erythematosus, as well as for use in organ and tissue transplantation; biopharmaceutical compositions and preparations, in particular those for use in the treatment of immunological conditions, tissue, stem cell and organ transplants, tumors and immune system conditions; medicinal preparations for the treatment of infectious diseases and for use in oncology and hematology; medicinal preparations for use in stem cell transplant procedures; medicinal preparations for use in organ transplant procedures.
